Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Sep;153(3):642-645.
doi: 10.1053/j.gastro.2017.07.029. Epub 2017 Jul 27.

Sugar, Sugar . . . Not So Sweet for the Liver

Miriam B Vos  1 , Michael I Goran  2
Affiliations
Editorial

Sugar, Sugar . . . Not So Sweet for the Liver

Miriam B Vos et al. Gastroenterology. 2017 Sep.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Fructose metabolism in NAFLD. Fructose is quickly transported from the gut to the liver through portal blood. Once in the liver, it is up-taken into hepatocytes rapidly, because of 10 fold higher levels in portal blood compared to other tissues and first pass clearance metabolism. In the liver, hepatic fat is derived from hepatic de novo lipogenesis (DNL), from the diet or from esterification of free fatty acids (FFA). Fructose promotes DNL which is already increased in NAFLD, and inhibits β oxidation, promoting accumulation of hepatic steatosis. Increased triglyceride from DNL is exported out of the liver through large very low density lipoproteins (VLDL), which contributes to dyslipidemia, increased low density lipoprotein (LDL) and development of atherosclerosis. The cycle of dysfunction continues as lipoprotein remnants of the large VLDL and FFA from visceral and subcutaneous adipose tissue are channeled back towards the liver contributing to lipid overload.
See this image and copyright information in PMC

Comment on

References

    1. Schwarz J-M, Noworolski SM, Erkin-Cakmak A, et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 2017;153:743–752. - PMC - PubMed
    1. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr 2013; 162:496–500. - PMC - PubMed
    1. Newton KP, Hou J, Crimmins NA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 2016:e161971. - PMC - PubMed
    1. Schwimmer JB, Pardee PE, Lavine JE, et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118:277–283. - PMC - PubMed
    1. Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319–334. - PMC - PubMed

LinkOut - more resources